Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.

Date publication

juillet 2016

Journal

The Lancet. Infectious diseases

Auteurs

Membres identifiés du Cancéropôle Est :
Pr HERBRECHT Raoul

Tous les auteurs :
Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Ráčil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JA, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild MJ,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26969258

Résumé

Mucormycosis is an uncommon invasive fungal disease with high mortality and few treatment options. Isavuconazole is a triazole active in vitro and in animal models against moulds of the order Mucorales. We assessed the efficacy and safety of isavuconazole for treatment of mucormycosis and compared its efficacy with amphotericin B in a matched case-control analysis.

Référence

Lancet Infect Dis. 2016 Jul;16(7):828-37